[go: up one dir, main page]

ZA969016B - Solubilisation methods. - Google Patents

Solubilisation methods.

Info

Publication number
ZA969016B
ZA969016B ZA9609016A ZA969016A ZA969016B ZA 969016 B ZA969016 B ZA 969016B ZA 9609016 A ZA9609016 A ZA 9609016A ZA 969016 A ZA969016 A ZA 969016A ZA 969016 B ZA969016 B ZA 969016B
Authority
ZA
South Africa
Prior art keywords
solubilisation
methods
solubilisation methods
Prior art date
Application number
ZA9609016A
Inventor
Roger Randal Charles New
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Publication of ZA969016B publication Critical patent/ZA969016B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA9609016A 1995-10-25 1996-10-25 Solubilisation methods. ZA969016B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9521805.3A GB9521805D0 (en) 1995-10-25 1995-10-25 Solubilisation methods

Publications (1)

Publication Number Publication Date
ZA969016B true ZA969016B (en) 1998-04-28

Family

ID=10782854

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9609016A ZA969016B (en) 1995-10-25 1996-10-25 Solubilisation methods.

Country Status (12)

Country Link
EP (1) EP0857061A1 (en)
JP (1) JP2000502990A (en)
KR (1) KR19990067028A (en)
CN (1) CN1202818A (en)
AU (1) AU704292B2 (en)
BR (1) BR9611343A (en)
CA (1) CA2235487A1 (en)
GB (1) GB9521805D0 (en)
NO (1) NO981864L (en)
NZ (1) NZ320442A (en)
WO (1) WO1997015289A1 (en)
ZA (1) ZA969016B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605709D0 (en) * 1996-03-19 1996-05-22 Cortecs Ltd Method
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
MX2008014870A (en) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator.
EP3421031A1 (en) 2006-08-09 2019-01-02 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
MX2009011123A (en) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof.
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
JP7077237B2 (en) 2016-05-16 2022-05-30 インターシア セラピューティクス,インコーポレイティド Glucagon Receptor Selective Polypeptides and Their Usage
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
MX2019008006A (en) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc METHODS INCLUDING THE CONTINUOUS ADMINISTRATION OF A GLP-1 RECEPTOR AGONIST AND THE CO-ADMINISTRATION OF A DRUG.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0012115A1 (en) * 1978-12-04 1980-06-11 Ciba-Geigy Ag Pharmaceutical compositions for topical treatment of virus infections
US4411882A (en) * 1978-12-21 1983-10-25 Sandoz Ltd. Galenical compositions

Also Published As

Publication number Publication date
NO981864D0 (en) 1998-04-24
AU704292B2 (en) 1999-04-15
AU7317896A (en) 1997-05-15
WO1997015289A1 (en) 1997-05-01
CA2235487A1 (en) 1997-05-01
KR19990067028A (en) 1999-08-16
BR9611343A (en) 1999-12-28
CN1202818A (en) 1998-12-23
NZ320442A (en) 1999-10-28
JP2000502990A (en) 2000-03-14
EP0857061A1 (en) 1998-08-12
GB9521805D0 (en) 1996-01-03
NO981864L (en) 1998-06-24

Similar Documents

Publication Publication Date Title
ZA967315B (en) Biphenylamides.
MX213417B (en) Phenylpyridazinones.
ZA9710429B (en) Broad-spectrumδ-endotoxins.
ZA979199B (en) Aminothiophenecarboxamides.
ZA976168B (en) 3-Ureido-pyridofurans and -pyridothiophenes.
ZA964468B (en) Triazolylmethyl-cyclopentanols.
ZA977206B (en) Arylalkanoylpyridazines.
ZA961955B (en) Indazolecarboxamides.
ZA978304B (en) 3-alkyl-3-phenyl-piperidines.
MXPA99002581A (en) Dredging apparatus.
ZA969016B (en) Solubilisation methods.
DE69610844D1 (en) Hydroformylierungsverfahren.
PL326837A1 (en) 25-hydroxy-16-ene-26, 27-bishomocholecarctiferoles
ZA966603B (en) Therapeutic method.
ZA97572B (en) 1-pyrazol-3-ylethyl-4-indol-3-ylpiperidines.
ZA966399B (en) Endothelin-receptor-antagonists.
ZA976022B (en) Cycloalkano-pyridines.
ZA966750B (en) Halogenobenzimidazoles.
ZA966933B (en) Endothelin-receptor-antagonists.
ZA971466B (en) Endothelin-receptor-antagonists.
ZA967314B (en) Carbamoylcarboxamides.
ZA966699B (en) Substituted 2-phenylpyridines.
ZA969560B (en) Substituted 1-methyl-3-phenylpyrazoles.
ZA971474B (en) Endothelin-receptor-antagonists.
ZA968953B (en) 24-homo-26,27-hexafluoro-cholecalciferols